Homoharringtonine Synergized with Gilteritinib Ends in the Downregulation of Myeloid Mobile Leukemia-1 through Upregulating UBE2L6 inside FLT3-ITD-Mutant Severe Myeloid (The leukemia disease) Cell Outlines.